In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its value as a second-line treatment in this indication.
There were thrice as many deaths in patients treated with ADC Therapeutics’ lymphoma drug Zynlonta as in controls given standard immunotherapy, causing the biotech’s share price to crash more than 50% to $1.44 per share and potentially complicating t... [2683 chars]